Meet Biotech’s kingmakers.
RA Capital and OrbiMed each led at least 10 private biotech rounds over the last five years, more than any other investor in our cohort. One firm led 6 rounds across just 7 companies.
This is the power map behind Biotech in private markets. 🧵